Embecta (EMBC) Q2 2026 Revenue Down 14.4% Year-Over-Year

Embecta (EMBC) reported a 14.4% decrease in revenue year-over-year for Q2 2026, driven primarily by U.S. weaknesses in its pen needle business. The company revised its fiscal 2026 revenue guidance to between $1.015 billion and $1.035 billion, down from a previous range of $1.071 billion to $1.093 billion. The revenue shortfall is attributed to a loss in market share and overall volume softness in the insulin pen market, particularly affecting a single major customer. Pen needles account for roughly 70% of the $75 million revenue reduction, estimated at around $53 million.

Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.